Form 4: Apogee Therapeutics Insider Trades Common Stock

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., reported transactions involving the acquisition and disposition of company common stock on April 1, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Carl Dambkowski, Chief Medical Officer at Apogee Therapeutics, Inc., engaged in several transactions on April 1, 2026.
• He acquired 4,125 shares of common stock at a price of $22.86 per share.
• He also disposed of a total of 5,500 shares of common stock through multiple sales.
• These sales were executed at weighted average prices of $84.31 and $85.33, with individual transactions ranging within specific price bands.
• Following these transactions, Dambkowski beneficially owns 208,398 shares of common stock.
• The acquisition of shares was made pursuant to a stock option, representing the right to purchase common stock at $22.86 per share.
• The dispositions were made under a Rule 10b5-1 trading plan adopted on September 22, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it reports insider transactions, the execution under a pre-established Rule 10b5-1 plan mitigates significant negative sentiment, though any sale by an executive warrants attention.

Positives

• Acquisition of 4,125 shares of common stock at a favorable price of $22.86, likely through the exercise of stock options.
• The reporting person continues to hold a significant number of shares (208,398) after the reported transactions, indicating continued investment in the company.

Negatives

• Disposition of 5,500 shares of common stock, indicating a reduction in direct holdings by a key executive.
• The sales occurred at prices significantly higher than the acquisition price, suggesting profit-taking.

Risks

• The sale of shares by a Chief Medical Officer could be interpreted by the market as a lack of confidence in future price appreciation, although executed under a pre-planned trading strategy.
• The Rule 10b5-1 plan is designed to mitigate insider trading concerns, but the execution of sales can still influence market perception.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the biotechnology sector as executives manage personal finances while adhering to regulatory requirements. The timing and volume of such trades can still be scrutinized by investors for potential signals about the company's internal outlook.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a key executive, even under a plan, as a potential signal, though the acquisition of shares offsets this concern.
• Employees: May observe insider trading activity as a general indicator of executive confidence or financial planning.
• Creditors: Unlikely to be significantly impacted by this type of transaction.

Next Steps

• The reporting person may be required to provide further details on specific sale prices upon request from the SEC or security holders.

Key Dates

Keywords

Form 4, Insider Trading, Apogee Therapeutics, APGE, Carl Dambkowski, Common Stock, Stock Options, Rule 10b5-1, Beneficial Ownership, Securities Exchange Act